Michael  Raab net worth and biography

Michael Raab Biography and Net Worth

CEO of Ardelyx
President & Chief Executive OfficerMike has served as Ardelyx’s President and Chief Executive Officer since March 2009. Before Ardelyx, Mike was a partner at New Enterprise Associates (NEA), one of the world’s largest and most successful venture capital firms, where he specialized in healthcare investments focusing on the biotechnology and pharmaceutical sectors.

Prior to joining NEA in 2002, Mike spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He was senior vice president, therapeutics and general manager of the renal division at Genzyme Corporation, a Sanofi company. In this position, Mike launched and oversaw the sales growth of sevelamer, the leading phosphate binder for the treatment of hyperphosphatemia, with over $1.0 billion in worldwide sales in 2013. Mike was also instrumental in the worldwide launch of Genzyme’s therapies for Gaucher disease, Ceredase and Cerezyme. Mike also spent two years with Genzyme’s diagnostic products and services division. Previous to Genzyme, Mike held business development and sales and marketing positions at Repligen and Bristol-Myers.

What is Michael Raab's net worth?

The estimated net worth of Michael Raab is at least $9.64 million as of February 20th, 2024. Mr. Raab owns 1,319,951 shares of Ardelyx stock worth more than $9,635,642 as of March 28th. This net worth approximation does not reflect any other investments that Mr. Raab may own. Additionally, Mr. Raab receives an annual salary of $1,280,000.00 as CEO at Ardelyx. Learn More about Michael Raab's net worth.

How old is Michael Raab?

Mr. Raab is currently 59 years old. There are 5 older executives and no younger executives at Ardelyx. Learn More on Michael Raab's age.

What is Michael Raab's salary?

As the CEO of Ardelyx, Inc., Mr. Raab earns $1,280,000.00 per year. Learn More on Michael Raab's salary.

How do I contact Michael Raab?

The corporate mailing address for Mr. Raab and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at [email protected]. Learn More on Michael Raab's contact information.

Has Michael Raab been buying or selling shares of Ardelyx?

During the last quarter, Michael Raab has sold $200,523.75 of Ardelyx stock. Most recently, Michael Raab sold 22,917 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $8.75, for a transaction totalling $200,523.75. Following the completion of the sale, the chief executive officer now directly owns 1,319,951 shares of the company's stock, valued at $11,549,571.25. Learn More on Michael Raab's trading history.

Who are Ardelyx's active insiders?

Ardelyx's insider roster includes Robert Blanks (Insider), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Michael Raab (CEO), David Rosenbaum (Insider), and Scott Sandell (Major Shareholder). Learn More on Ardelyx's active insiders.

Are insiders buying or selling shares of Ardelyx?

In the last year, insiders at the biopharmaceutical company sold shares 30 times. They sold a total of 637,490 shares worth more than $3,824,112.43. The most recent insider tranaction occured on March, 20th when insider Elizabeth A Grammer sold 86,000 shares worth more than $664,780.00. Insiders at Ardelyx own 5.5% of the company. Learn More about insider trades at Ardelyx.

Information on this page was last updated on 3/20/2024.

Michael Raab Insider Trading History at Ardelyx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/20/2024Sell22,917$8.75$200,523.751,319,951View SEC Filing Icon  
11/20/2023Sell11,368$4.36$49,564.48867,868View SEC Filing Icon  
8/21/2023Sell11,419$3.55$40,537.45876,236View SEC Filing Icon  
5/23/2023Sell11,357$3.65$41,453.05887,655View SEC Filing Icon  
2/21/2023Sell13,449$3.00$40,347.00896,012View SEC Filing Icon  
8/22/2022Sell6,146$0.98$6,023.08662,680View SEC Filing Icon  
6/6/2022Sell103,624$0.65$67,355.60668,826View SEC Filing Icon  
5/20/2022Sell6,124$0.67$4,103.08772,450View SEC Filing Icon  
2/22/2022Sell6,229$0.67$4,173.43View SEC Filing Icon  
11/22/2021Sell2,607$0.99$2,580.93View SEC Filing Icon  
8/20/2021Sell2,573$1.32$3,396.36329,730View SEC Filing Icon  
5/20/2021Sell2,534$7.09$17,966.06214,754View SEC Filing Icon  
9/15/2020Sell106,337$5.61$596,550.57View SEC Filing Icon  
7/2/2020Sell23,128$7.01$162,127.28
6/1/2020Sell23,128$7.33$169,528.24208,057View SEC Filing Icon  
5/4/2020Sell15,941$7.01$111,746.41208,057View SEC Filing Icon  
4/17/2020Sell9,428$7.02$66,184.56208,057View SEC Filing Icon  
4/15/2020Sell500$7.03$3,515.00208,057View SEC Filing Icon  
3/2/2020Sell11,123$7.00$77,861.00View SEC Filing Icon  
2/5/2020Sell25,000$7.32$183,000.00View SEC Filing Icon  
6/4/2019Sell10,054$2.54$25,537.16View SEC Filing Icon  
1/2/2019Sell19,644$1.70$33,394.80View SEC Filing Icon  
9/8/2015Sell9,785$20.29$198,537.651,518View SEC Filing Icon  
See Full Table

Michael Raab Buying and Selling Activity at Ardelyx

This chart shows Michael Raab's buying and selling at Ardelyx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ardelyx Company Overview

Ardelyx logo
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $7.30
Low: $7.25
High: $7.59

50 Day Range

MA: $8.74
Low: $7.30
High: $9.74

2 Week Range

Now: $7.30
Low: $3.16
High: $10.13

Volume

6,718,669 shs

Average Volume

6,321,907 shs

Market Capitalization

$1.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88